Acetophenazine

CHEMBL1085 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

411.6 g/mol

LogP

2.6

Phase

4

An older antipsychotic medication from the phenothiazine class that was used to treat schizophrenia and other serious psychiatric conditions by blocking dopamine receptors in the brain. It reduces hallucinations, delusions, and disorganized thinking but carries a risk of movement-related side effects known as extrapyramidal symptoms, including tremors and involuntary muscle movements. It has been largely superseded by newer antipsychotic medications with improved tolerability profiles.

الوزن الجزيئي

411,6000 g/mol

LogP

2,60

TPSA

72,30 Å²

قاعدة ليبينسكي للخمسة

ناجح

آلية العمل

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2

InChI

InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3

Molecular Formula

C23H29N3O2S

HBD / HBA

1 / 6

الروابط القابلة للدوران

7

الذرات الثقيلة

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An older antipsychotic medication from the phenothiazine class that was used to treat schizophrenia and other serious psychiatric conditions by blocking dopamine receptors in the brain. It reduces hallucinations, delusions, and disorganized thinking but carries a risk of movement-related side effects known as extrapyramidal symptoms, including tremors and involuntary muscle movements. It has been largely superseded by newer antipsychotic medications with improved tolerability profiles.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Acetophenazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1085. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 17676. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Acetophenazine على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C23H29N3O2S

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.